Gilead Speeds Up Production of Experimental COVID-19 Drug, Stock Up 7%
Gilead (NASDAQ:GILD) said it has accelerated production time of Remdesivir, considered to be the most promising existing therapeutic candidate for COVID-19, from one year to six months. In the meantime, shares of the company are trading near the multi-year highs, despite the wider market selloff. Fu
Sep 26, 2024